Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. méd. Chile ; 146(5): 562-569, mayo 2018. tab, graf
Article Dans Espagnol | LILACS | ID: biblio-961432

Résumé

Background: Deep brain stimulation is an essential therapeutic tool in Parkinson's disease. Aim: To assess the results of a series of patients with Parkinson's disease treated with micro-electrode guided subthalamic nucleus stimulation. Material and Methods: Twenty patients with idiopathic Parkinson's disease were studied (10 males). Three months after surgery, we analyzed the change in motor disturbances, medication need to control symptoms and quality of life. Results: We observed a significant improvement in all the assessed variables. Motor involvement determined as OFF hours and expressed as percentage of the day changed from 30 ± 15 to 10 ± 7% in the preoperative and postoperative periods, respectively. ON hours without dyskinesia changed from 17 ± 16 to 78 ± 21%. ON hours with dyskinesia changed from 53 ± 23 to 12 ± 15%. Medication need changed from 1,505 ± 499 to 1,214 ± 528 levodopa equivalents. Parkinson's Disease Questionnaire 39 score changed from 62.9 ± 22.7 to 34.3 ± 18.5. During the 5-year follow-up a continuous improvement of symptoms was observed. Conclusions: Micro-electrode guided subthalamic nucleus functional surgery in patients with Parkinson's disease has good immediate and late results.


Sujets)
Humains , Mâle , Femelle , Adulte d'âge moyen , Maladie de Parkinson/chirurgie , Noyau subthalamique/chirurgie , Stimulation cérébrale profonde/méthodes , Qualité de vie , Indice de gravité de la maladie , Études rétrospectives , Résultat thérapeutique , Stimulation cérébrale profonde/effets indésirables
2.
Rev. chil. neuro-psiquiatr ; 41(2): 139-144, abr.-jun. 2003.
Article Dans Espagnol | LILACS | ID: lil-383465

Résumé

A dos décadas de la aparición de las primeras publicaciones sobre los usos terapéuticos de la toxina botulínica (TB), presentamos una revisión sobre la situación de esta terapia en pacientes con distonía, analizando efectividad, seguridad y complicaciones. Se comentan aspectos en controversia tales como: valor de la determinación de anticuerpos, correlación de éstos con la respuesta clínica y homologación de las unidades de TB, para las formulaciones de tipos A y B, disponibles en el mercado.


Sujets)
Humains , Dystonie/traitement médicamenteux , Toxines botuliniques/administration et posologie , Toxines botuliniques/effets indésirables , Toxines botuliniques/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche